Published in Emerg Infect Dis on June 01, 2005
Pre- and postvaccination clonal compositions of invasive pneumococcal serotypes for isolates collected in the United States in 1999, 2001, and 2002. J Clin Microbiol (2006) 2.46
Hidden epidemic of macrolide-resistant pneumococci. Emerg Infect Dis (2005) 1.68
The mef(E)-carrying genetic element (mega) of Streptococcus pneumoniae: insertion sites and association with other genetic elements. Antimicrob Agents Chemother (2006) 1.64
Increase in pneumococcus macrolide resistance, United States. Emerg Infect Dis (2009) 1.54
The macrolide resistance genes erm(B) and mef(E) are carried by Tn2010 in dual-gene Streptococcus pneumoniae isolates belonging to clonal complex CC271. Antimicrob Agents Chemother (2007) 1.46
Trends in antibacterial resistance among Streptococcus pneumoniae isolated in the USA: update from PROTEKT US Years 1-4. Ann Clin Microbiol Antimicrob (2008) 1.29
Serotypes, Clones, and Mechanisms of Resistance of Erythromycin-Resistant Streptococcus pneumoniae Isolates Collected in Spain. Antimicrob Agents Chemother (2007) 1.28
Clinical implications of pneumococcal serotypes: invasive disease potential, clinical presentations, and antibiotic resistance. J Korean Med Sci (2013) 1.04
In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens. Antimicrob Agents Chemother (2008) 0.93
Molecular typing methods for outbreak detection and surveillance of invasive disease caused by Neisseria meningitidis, Haemophilus influenzae and Streptococcus pneumoniae, a review. Microbiology (2011) 0.93
Polyclonal population structure of Streptococcus pneumoniae isolates in Spain carrying mef and mef plus erm(B). Antimicrob Agents Chemother (2008) 0.93
Bacteremic pneumococcal pneumonia associated with macrolide failure. Eur J Clin Microbiol Infect Dis (2006) 0.93
In vitro antibacterial activity of modithromycin, a novel 6,11-bridged bicyclolide, against respiratory pathogens, including macrolide-resistant Gram-positive cocci. Antimicrob Agents Chemother (2011) 0.90
Mechanisms of macrolide resistance among Streptococcus pneumoniae isolates from Russia. Antimicrob Agents Chemother (2008) 0.90
Oropharyngeal colonization by Streptococcus pneumoniae among HIV-infected adults in Uganda: assessing prevalence and antimicrobial susceptibility. Int J Infect Dis (2006) 0.90
Distribution of serotypes, genotypes, and resistance determinants among macrolide-resistant Streptococcus pneumoniae isolates. Antimicrob Agents Chemother (2010) 0.89
New composite genetic element of the Tn916 family with dual macrolide resistance genes in a Streptococcus pneumoniae isolate belonging to clonal complex 271. Antimicrob Agents Chemother (2008) 0.88
Prevalence and antibacterial susceptibility of mef(A)-positive macrolide-resistant Streptococcus pneumoniae over 4 years (2000 to 2004) of the PROTEKT US Study. J Clin Microbiol (2006) 0.88
Increase of the M phenotype among erythromycin-resistant Streptococcus pneumoniae isolates from Spain related to the serotype 14 variant of the Spain9V-3 clone. Antimicrob Agents Chemother (2006) 0.86
Emerging non-PCV13 serotypes of noninvasive Streptococcus pneumoniae with macrolide resistance genes in northern Japan. New Microbes New Infect (2015) 0.84
Antibiotic innovation may contribute to slowing the dissemination of multiresistant Streptococcus pneumoniae: the example of ketolides. PLoS One (2008) 0.83
Dominance of multidrug resistant CC271 clones in macrolide-resistant streptococcus pneumoniae in Arizona. BMC Microbiol (2012) 0.83
Clonal spread of mef-positive macrolide-resistant Streptococcus pneumoniae isolates causing invasive disease in adults in Germany. Antimicrob Agents Chemother (2007) 0.82
Genotypes and related factors reflecting macrolide resistance in pneumococcal pneumonia infections in Japan. J Clin Microbiol (2007) 0.82
Molecular resistance mechanisms of macrolide-resistant invasive Streptococcus pneumoniae isolates from Alaska, 1986 to 2010. Antimicrob Agents Chemother (2013) 0.82
Induction of efflux-mediated macrolide resistance in Streptococcus pneumoniae. Antimicrob Agents Chemother (2011) 0.81
Macrolide resistance determinants among Streptococcus pneumoniae isolates from carriers in Central Greece. BMC Infect Dis (2012) 0.81
Increasing penicillin and trimethoprim-sulfamethoxazole resistance in nasopharyngeal Streptococcus pneumoniae isolates from Guatemalan children, 2001--2006. Int J Infect Dis (2007) 0.80
Emergence of Amoxicillin-Resistant Variants of Spain9V-ST156 Pneumococci Expressing Serotype 11A Correlates with Their Ability to Evade the Host Immune Response. PLoS One (2015) 0.79
Serotype distribution and antibiotics susceptibility pattern of Streptococcus pneumonia in Iran. Iran Red Crescent Med J (2013) 0.79
Increase in the rate of azithromycin-resistant Streptococcus pneumoniae isolates carrying the erm(B) and mef(A) genes in Taiwan, 2006-2010. BMC Infect Dis (2014) 0.79
Phenotypes and genotypes of macrolide-resistant streptococcus pneumoniae. Balkan Med J (2015) 0.79
Resistance determinants and their association with different transposons in the antibiotic-resistant Streptococcus pneumoniae. Biomed Res Int (2015) 0.78
The Value of Macrolide-Based Regimens for Community-Acquired Pneumonia. Curr Infect Dis Rep (2015) 0.76
Determination of Characteristics of Erythromycin Resistant Streptococcus pneumoniae with Preferred PCV Usage in Iran. PLoS One (2016) 0.75
Synthesis and antibacterial activity of novel 11-[3-[(arylcarbamoyl)oxy]propylamino]-11-deoxy-6-O-methyl-3-oxoerythromycin A 11-N,12-O-cyclic carbamate derivatives. J Antibiot (Tokyo) (2016) 0.75
Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med (2001) 10.56
Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med (2001) 9.08
Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States. N Engl J Med (2000) 8.05
Sequence type analysis and recombinational tests (START). Bioinformatics (2001) 7.20
Bacterial resistance to macrolide, lincosamide, and streptogramin antibiotics by target modification. Antimicrob Agents Chemother (1991) 7.18
Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America: 1997 results from the SENTRY antimicrobial surveillance program. Clin Infect Dis (1998) 3.76
Decrease of invasive pneumococcal infections in children among 8 children's hospitals in the United States after the introduction of the 7-valent pneumococcal conjugate vaccine. Pediatrics (2004) 3.71
Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999--2000, including a comparison of resistance rates since 1994--1995. Antimicrob Agents Chemother (2001) 3.23
Molecular characterization of penicillin-resistant Streptococcus pneumoniae isolates causing respiratory disease in the United States. Microb Drug Resist (1998) 2.62
Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis (2001) 2.39
Increasing prevalence of antimicrobial resistance among isolates of Streptococcus pneumoniae from the PROTEKT surveillance study, and compatative in vitro activity of the ketolide, telithromycin. J Antimicrob Chemother (2002) 2.30
The Alexander Project 1996-1997: latest susceptibility data from this international study of bacterial pathogens from community-acquired lower respiratory tract infections. J Antimicrob Chemother (2000) 2.27
Molecular characterization of macrolide resistance mechanisms among Streptococcus pneumoniae and Streptococcus pyogenes isolated from the PROTEKT 1999-2000 study. J Antimicrob Chemother (2002) 2.08
Antimicrobial treatment guidelines for acute bacterial rhinosinusitis. Otolaryngol Head Neck Surg (2004) 1.99
The molecular epidemiology of penicillin-resistant Streptococcus pneumoniae in the United States, 1994-2000. Clin Infect Dis (2001) 1.91
Postlicensure surveillance for pneumococcal invasive disease after use of heptavalent pneumococcal conjugate vaccine in Northern California Kaiser Permanente. Pediatr Infect Dis J (2004) 1.90
Molecular epidemiology of erythromycin resistance in Streptococcus pneumoniae isolates from blood and noninvasive sites. J Clin Microbiol (2002) 1.71
Serotype 19f multiresistant pneumococcal clone harboring two erythromycin resistance determinants (erm(B) and mef(A)) in South Africa. Antimicrob Agents Chemother (2001) 1.60
Phenotypes and genotypes of erythromycin-resistant pneumococci in Italy. J Clin Microbiol (2003) 1.53
Detection of macrolide resistance mechanisms in Streptococcus pneumoniae and Streptococcus pyogenes using a multiplex rapid cycle PCR with microwell-format probe hybridization. J Antimicrob Chemother (2001) 1.48
Molecular epidemiology of multiresistant Streptococcus pneumoniae with both erm(B)- and mef(A)-mediated macrolide resistance. J Clin Microbiol (2004) 1.43
Evolution of erythromycin-resistant Streptococcus pneumoniae from Asian countries that contains erm(B) and mef(A) genes. J Infect Dis (2004) 1.41
Epidemiology and treatment of chronic bronchitis and its exacerbations. Chest (1995) 1.25
Kinetics and avidity of antibodies evoked by heptavalent pneumococcal conjugate vaccines PncCRM and PncOMPC in the Finnish Otitis Media Vaccine Trial. Infect Immun (2005) 1.21
Antimicrobial susceptibility of community-acquired respiratory tract pathogens in North America in 1999-2000: findings of the PROTEKT surveillance study. Diagn Microbiol Infect Dis (2003) 1.21
Antimicrobial susceptibility among community-acquired respiratory tract pathogens in the USA: data from PROTEKT US 2000-01. J Infect (2004) 1.18
Streptococcus pneumoniae and Streptococcus pyogenes isolated from a paediatric population in Great Britain and Ireland: the in vitro activity of telithromcycin versus comparators. J Infect (2004) 1.02
Prevalence of serotypes and molecular epidemiology of Streptococcus pneumoniae strains isolated from children in Beijing, China: identification of two novel multiply-resistant clones. Microb Drug Resist (2001) 1.00
What Is the Clinical Impact of Macrolide Resistance? Curr Infect Dis Rep (2004) 1.00
The need for antimicrobial resistance surveillance. J Antimicrob Chemother (2002) 0.99
Susceptibilities to levofloxacin in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis clinical isolates from children: results from 2000-2001 and 2001-2002 TRUST studies in the United States. Antimicrob Agents Chemother (2003) 0.96
Treatment of acute otitis media consensus recommendations. Clin Pediatr (Phila) (2002) 0.95
Genotypic characterization of macrolide-resistant strains of Streptococcus pneumoniae isolated in Quebec, Canada, and in vitro activity of ABT-773 and telithromycin. J Antimicrob Chemother (2002) 0.94
The hidden impact of antibacterial resistance in respiratory tract infection. Clinical failures: the tip of the iceberg? Respir Med (2001) 0.86
Dissemination of macrolide-resistant Streptococcus pneumoniae isolates containing both erm(B) and mef(A) in South Korea. J Clin Microbiol (2003) 0.84
Prevalence of erm(A) and mef(B) erythromycin resistance determinants in isolates of Streptococcus pneumoniae from New Zealand. J Antimicrob Chemother (2002) 0.80
Rapid pneumococcal evolution in response to clinical interventions. Science (2011) 9.09
Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect Control Hosp Epidemiol (2008) 7.38
Antimicrobial resistance in developing countries. Part I: recent trends and current status. Lancet Infect Dis (2005) 5.58
Global burden of respiratory infections due to seasonal influenza in young children: a systematic review and meta-analysis. Lancet (2011) 5.43
International prospective study of Klebsiella pneumoniae bacteremia: implications of extended-spectrum beta-lactamase production in nosocomial Infections. Ann Intern Med (2004) 4.75
Community-acquired Klebsiella pneumoniae bacteremia: global differences in clinical patterns. Emerg Infect Dis (2002) 4.08
The self-efficacy-interest relationship and RIASEC type: Which is figure and which is ground? Comment on Armstrong and Vogel (2009). J Couns Psychol (2010) 3.99
An international prospective study of pneumococcal bacteremia: correlation with in vitro resistance, antibiotics administered, and clinical outcome. Clin Infect Dis (2003) 3.93
Characterization of blaKPC-containing Klebsiella pneumoniae isolates detected in different institutions in the Eastern USA. J Antimicrob Chemother (2009) 3.82
Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases. Clin Infect Dis (2004) 3.75
Epidemiological differences among pneumococcal serotypes. Lancet Infect Dis (2005) 3.72
Influenza vaccination of pregnant women and protection of their infants. N Engl J Med (2014) 3.68
Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia. Am J Respir Crit Care Med (2004) 3.49
A role for Streptococcus pneumoniae in virus-associated pneumonia. Nat Med (2004) 3.49
The genetic basis for bacterial mercury methylation. Science (2013) 2.87
The impact of a 9-valent pneumococcal conjugate vaccine on the public health burden of pneumonia in HIV-infected and -uninfected children. Clin Infect Dis (2005) 2.81
Ricin poisoning: a comprehensive review. JAMA (2005) 2.62
Association of serotype with risk of death due to pneumococcal pneumonia: a meta-analysis. Clin Infect Dis (2010) 2.50
Virulence characteristics of Klebsiella and clinical manifestations of K. pneumoniae bloodstream infections. Emerg Infect Dis (2007) 2.49
Impact of pneumococcal conjugate vaccination of infants on pneumonia and influenza hospitalization and mortality in all age groups in the United States. MBio (2011) 2.48
Density interactions among Streptococcus pneumoniae, Haemophilus influenzae and Staphylococcus aureus in the nasopharynx of young Peruvian children. Pediatr Infect Dis J (2013) 2.47
Pneumococcal vaccination in developing countries. Lancet (2006) 2.45
Comparative sequence analysis of the symbiosis island of Mesorhizobium loti strain R7A. J Bacteriol (2002) 2.37
Decreased susceptibility to polymyxin B during treatment for carbapenem-resistant Klebsiella pneumoniae infection. J Clin Microbiol (2009) 2.30
Effect of rotavirus vaccination on death from childhood diarrhea in Mexico. N Engl J Med (2010) 2.26
Novel mechanism of resistance to oxazolidinones, macrolides, and chloramphenicol in ribosomal protein L4 of the pneumococcus. Antimicrob Agents Chemother (2005) 2.14
Impact of conjugate pneumococcal vaccines on antibiotic resistance. Lancet Infect Dis (2008) 2.11
Ineffectiveness of trimethoprim-sulfamethoxazole prophylaxis and the importance of bacterial and viral coinfections in African children with Pneumocystis carinii pneumonia. Clin Infect Dis (2002) 2.07
Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies. Vaccine (2007) 2.07
Increased antimicrobial resistance among nonvaccine serotypes of Streptococcus pneumoniae in the pediatric population after the introduction of 7-valent pneumococcal vaccine in the United States. Pediatr Infect Dis J (2007) 2.06
Antimicrobial resistance in developing countries. Part II: strategies for containment. Lancet Infect Dis (2005) 2.05
Increased prevalence of pediatric pneumococcal serotypes in elderly adults. Clin Infect Dis (2005) 2.03
Vitamin D intake to attain a desired serum 25-hydroxyvitamin D concentration. Am J Clin Nutr (2008) 2.00
Fitness costs of fluoroquinolone resistance in Streptococcus pneumoniae. Antimicrob Agents Chemother (2006) 1.98
In vitro bactericidal activity of daptomycin against staphylococci. J Antimicrob Chemother (2002) 1.97
The global challenge of carbapenem-resistant Enterobacteriaceae in transplant recipients and patients with hematologic malignancies. Clin Infect Dis (2014) 1.94
Fine needle aspiration of a neck lump: a mercurial mystery. Br J Oral Maxillofac Surg (2009) 1.93
Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis. J Infect Dis (2009) 1.92
Workgroup report: public health strategies for reducing aflatoxin exposure in developing countries. Environ Health Perspect (2006) 1.89
Presence of plasmid-mediated quinolone resistance in Klebsiella pneumoniae isolates possessing blaKPC in the United States. Antimicrob Agents Chemother (2008) 1.89
A high utility integrated map of the pig genome. Genome Biol (2007) 1.88
Complete genome sequence of the cellulolytic thermophile Caldicellulosiruptor obsidiansis OB47T. J Bacteriol (2010) 1.86
Effects of vaccination on invasive pneumococcal disease in South Africa. N Engl J Med (2014) 1.84
Decline in diarrhea mortality and admissions after routine childhood rotavirus immunization in Brazil: a time-series analysis. PLoS Med (2011) 1.83
Quantitative and qualitative anamnestic immune responses to pneumococcal conjugate vaccine in HIV-infected and HIV-uninfected children 5 years after vaccination. J Infect Dis (2009) 1.82
Increased risk of invasive bacterial infections in African people with sickle-cell disease: a systematic review and meta-analysis. Lancet Infect Dis (2010) 1.82
Maternal influenza immunization and reduced likelihood of prematurity and small for gestational age births: a retrospective cohort study. PLoS Med (2011) 1.82
Early detection of illness associated with poisonings of public health significance. Ann Emerg Med (2005) 1.80
Rotavirus vaccines: successes and challenges. J Infect (2013) 1.74
Rationale for revised penicillin susceptibility breakpoints versus Streptococcus pneumoniae: coping with antimicrobial susceptibility in an era of resistance. Clin Infect Dis (2009) 1.69
Historical changes in pneumococcal serogroup distribution: implications for the era of pneumococcal conjugate vaccines. Clin Infect Dis (2002) 1.66
Robotic-assisted nephroureterectomy and bladder cuff excision without intraoperative repositioning. Urology (2011) 1.64
Outpatient antibiotic prescribing and nonsusceptible Streptococcus pneumoniae in the United States, 1996-2003. Clin Infect Dis (2011) 1.63
Use of active surveillance cultures to detect asymptomatic colonization with carbapenem-resistant Klebsiella pneumoniae in intensive care unit patients. Infect Control Hosp Epidemiol (2008) 1.63
Postlicensure monitoring of intussusception after RotaTeq vaccination in the United States, February 1, 2006, to September 25, 2007. Pediatrics (2008) 1.63
Impact of an antimicrobial utilization program on antimicrobial use at a large teaching hospital: a randomized controlled trial. Infect Control Hosp Epidemiol (2009) 1.60
Denitrifying bacteria isolated from terrestrial subsurface sediments exposed to mixed-waste contamination. Appl Environ Microbiol (2010) 1.58
Comparison of meropenem MICs and susceptibilities for carbapenemase-producing Klebsiella pneumoniae isolates by various testing methods. J Clin Microbiol (2010) 1.57
Levofloxacin-resistant invasive Streptococcus pneumoniae in the United States: evidence for clonal spread and the impact of conjugate pneumococcal vaccine. Antimicrob Agents Chemother (2004) 1.53
Pneumococcal vaccines and flu preparedness. Science (2007) 1.50
Consensus-derived practice standards plan for complicated Kaposiform hemangioendothelioma. J Pediatr (2013) 1.48
Emergence of carbapenem-resistant Enterobacteriaceae as causes of bloodstream infections in patients with hematologic malignancies. Leuk Lymphoma (2012) 1.47
The anticipated severity of a "1918-like" influenza pandemic in contemporary populations: the contribution of antibacterial interventions. PLoS One (2012) 1.47
Multiplex real-time PCR for detection of an epidemic KPC-producing Klebsiella pneumoniae ST258 clone. Antimicrob Agents Chemother (2012) 1.46
Transcriptomic and metabolomic profiling of Zymomonas mobilis during aerobic and anaerobic fermentations. BMC Genomics (2009) 1.44
Emergence of fluoroquinolone-resistant Streptococcus pneumoniae in a South African child in a tuberculosis treatment facility. Pediatr Infect Dis J (2003) 1.44
Pneumococcal capsular switching: a historical perspective. J Infect Dis (2012) 1.43
Clinical breakpoints for voriconazole and Candida spp. revisited: review of microbiologic, molecular, pharmacodynamic, and clinical data as they pertain to the development of species-specific interpretive criteria. Diagn Microbiol Infect Dis (2011) 1.42
Disassembly of a rotablator: getting out of a trap. Catheter Cardiovasc Interv (2003) 1.42
Serotype 6C is associated with penicillin-susceptible meningeal infections in human immunodeficiency virus (HIV)-infected adults among invasive pneumococcal isolates previously identified as serotype 6A in South Africa. Int J Antimicrob Agents (2008) 1.40
Effect of HIV infection status and anti-retroviral treatment on quantitative and qualitative antibody responses to pneumococcal conjugate vaccine in infants. J Infect Dis (2010) 1.39
Effectiveness of rotavirus vaccination against childhood diarrhoea in El Salvador: case-control study. BMJ (2010) 1.39
The efficacy, safety and tolerability of intracavernous PNU-83757 for the treatment of erectile dysfunction. J Urol (2002) 1.39
World Health Organisation definition of "radiologically-confirmed pneumonia" may under-estimate the true public health value of conjugate pneumococcal vaccines. Vaccine (2006) 1.38
Comparative effectiveness of aminoglycosides, polymyxin B, and tigecycline for clearance of carbapenem-resistant Klebsiella pneumoniae from urine. Antimicrob Agents Chemother (2011) 1.37
Emergence of Streptococcus pneumoniae with very-high-level resistance to penicillin. Antimicrob Agents Chemother (2004) 1.36
Draft Genome Sequence of the Lignin-Degrading Burkholderia sp. Strain LIG30, Isolated from Wet Tropical Forest Soil. Genome Announc (2014) 1.34
Rhinosinusitis: developing guidance for clinical trials. J Allergy Clin Immunol (2006) 1.33
Role of Streptococcus pneumoniae in hospitalization for acute community-acquired pneumonia associated with culture-confirmed Mycobacterium tuberculosis in children: a pneumococcal conjugate vaccine probe study. Pediatr Infect Dis J (2010) 1.33
Influence of bacterial interactions on pneumococcal colonization of the nasopharynx. Trends Microbiol (2012) 1.33
Quantitative and qualitative antibody response to pneumococcal conjugate vaccine among African human immunodeficiency virus-infected and uninfected children. Pediatr Infect Dis J (2005) 1.31
Improved genome annotation for Zymomonas mobilis. Nat Biotechnol (2009) 1.30
A framework for global surveillance of antibiotic resistance. Drug Resist Updat (2011) 1.29
Trends in antibacterial resistance among Streptococcus pneumoniae isolated in the USA: update from PROTEKT US Years 1-4. Ann Clin Microbiol Antimicrob (2008) 1.29
Emergence of fluoroquinolone resistance among Bacteroides species. J Antimicrob Chemother (2003) 1.29
Reversion to susceptibility in a linezolid-resistant clinical isolate of Staphylococcus aureus. J Antimicrob Chemother (2004) 1.28
Regional trends in beta-lactam, macrolide, fluoroquinolone and telithromycin resistance among Streptococcus pneumoniae isolates 2001-2004. J Infect (2007) 1.27
Live attenuated influenza vaccine enhances colonization of Streptococcus pneumoniae and Staphylococcus aureus in mice. MBio (2014) 1.26
Epidemiology of invasive pneumococcal disease among high-risk adults since the introduction of pneumococcal conjugate vaccine for children. Clin Infect Dis (2012) 1.26
Sulfate-reducing bacterium Desulfovibrio desulfuricans ND132 as a model for understanding bacterial mercury methylation. Appl Environ Microbiol (2011) 1.26
Paradigm for industrial strain improvement identifies sodium acetate tolerance loci in Zymomonas mobilis and Saccharomyces cerevisiae. Proc Natl Acad Sci U S A (2010) 1.26
Global epidemiology of invasive meningococcal disease. Popul Health Metr (2013) 1.25
Epidemiology of Group B Streptococcus in developing countries. Vaccine (2013) 1.24
Communicating trends in resistance using a drug resistance index. BMJ Open (2011) 1.23
Public health and economic impact of the 13-valent pneumococcal conjugate vaccine (PCV13) in the United States. Vaccine (2010) 1.23
Predicting risk for death from MRSA bacteremia. Emerg Infect Dis (2012) 1.22
Transcriptome profiling of Shewanella oneidensis gene expression following exposure to acidic and alkaline pH. J Bacteriol (2006) 1.22